TY - JOUR
T1 - PReferentially Expressed Antigen in MElanoma (PRAME)
T2 - preliminary communication on a translational tool able to early detect Oral Malignant Melanoma (OMM)
AU - Cascardi, Eliano
AU - Cazzato, Gerardo
AU - Ingravallo, Giuseppe
AU - Dellino, Miriam
AU - Lupo, Carmelo
AU - Casatta, Nadia
AU - Ballini, Andrea
AU - Pacifici, Andrea
AU - Marenzi, Gaetano
AU - Sammartino, Gilberto
AU - Maiorano, Eugenio
AU - Tatullo, Marco
N1 - Copyright:
© The author(s).
PY - 2023/2/27
Y1 - 2023/2/27
N2 - Oral malignant melanoma (OMM) has a prevalence less than 1% of all melanomas and it commonly develops on the oral mucosa following a slow and unspecific transformation of unstable melanocytic lesions, often resulting in a diagnostic delay. The marker PReferentially Expressed Antigen in MElanoma (PRAME) seems to be a valid tool to investigate the biological and histological nature of cutaneous melanocytic lesions, but to date its use to characterize pigmented lesions in the oral cavity is largely unexplored. The aim of this study was to create preliminary knowledge on the PRAME expression in OMM, and to compare its expression respect to other dysplastic pigmented lesions of the oral cavity. Interestingly, PRAME has been demonstrated to be reliable in the clinical conditions investigated in our pilot study; in fact, it has clearly differentiated the cases of Melanoma, which showed diffuse and intense positivity (score 6+/7+) to PRAME, from the other melanocytic nevi, which resulted to be mainly negative to PRAME. This means a better differential diagnosis, a reliable early diagnosis and a proper clinical/surgical management of the oncological lesions. In conclusion, PRAME can be a valid qualitative marker for differential diagnosis, not only in cutaneous melanomas, but also in malignant melanoma of the entire head and neck area.
AB - Oral malignant melanoma (OMM) has a prevalence less than 1% of all melanomas and it commonly develops on the oral mucosa following a slow and unspecific transformation of unstable melanocytic lesions, often resulting in a diagnostic delay. The marker PReferentially Expressed Antigen in MElanoma (PRAME) seems to be a valid tool to investigate the biological and histological nature of cutaneous melanocytic lesions, but to date its use to characterize pigmented lesions in the oral cavity is largely unexplored. The aim of this study was to create preliminary knowledge on the PRAME expression in OMM, and to compare its expression respect to other dysplastic pigmented lesions of the oral cavity. Interestingly, PRAME has been demonstrated to be reliable in the clinical conditions investigated in our pilot study; in fact, it has clearly differentiated the cases of Melanoma, which showed diffuse and intense positivity (score 6+/7+) to PRAME, from the other melanocytic nevi, which resulted to be mainly negative to PRAME. This means a better differential diagnosis, a reliable early diagnosis and a proper clinical/surgical management of the oncological lesions. In conclusion, PRAME can be a valid qualitative marker for differential diagnosis, not only in cutaneous melanomas, but also in malignant melanoma of the entire head and neck area.
KW - Differential Diagnosis
KW - Early diagnosis
KW - Oral Malignant Melanoma
UR - http://www.scopus.com/inward/record.url?scp=85152208760&partnerID=8YFLogxK
U2 - 10.7150/jca.82389
DO - 10.7150/jca.82389
M3 - Article
C2 - 37057287
AN - SCOPUS:85152208760
SN - 1837-9664
VL - 14
SP - 628
EP - 633
JO - Journal of Cancer
JF - Journal of Cancer
IS - 4
ER -